Molecular Formula | C19H21FN4O3S |
Molar Mass | 404.46 |
Density | 1.47±0.1 g/cm3(Predicted) |
Boling Point | 553.7±60.0 °C(Predicted) |
Solubility | DMSO : 62.5 mg/mL (154.53 mM; Need ultrasonic) |
pKa | 1.29±0.20(Predicted) |
Storage Condition | 2-8°C(protect from light) |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.472 ml | 12.362 ml | 24.724 ml |
5 mM | 0.494 ml | 2.472 ml | 4.945 ml |
10 mM | 0.247 ml | 1.236 ml | 2.472 ml |
5 mM | 0.049 ml | 0.247 ml | 0.494 ml |
biological activity | CLP290 is an oral activator of the neuro-specific K -Cl − cotransporter KCC2, it has the potential to study a variety of neurological and psychiatric disorders. CLP290 can significantly reduce the level of AVP and blood glucose in the blood of STZ rats. |
Target | KCC2 |
Animal Model: | Adult male rats (300 g, >postnatal day 60) |
Dosage: | 100 mg/kg |
Administration: | Oral gavage; 100 mg/kg; twice a day; 7day |
Result: | Rescued established MIH and prevented its development by restoring Cl - transport or preventing its deficiency in the SDH. |